Clinical trials: FLU
Influenza
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults
The main purpose of the study is to evaluate the safety, reactogenicity, and the immunogenicity of mRNA-1010 vaccine candidate variations.
- Trial name
- NCT05868382
- Testing
- mRNA-1010, mRNA-1010.4, mRNA-1010.6
- Where
- 10 sites in United States
- Volunteers
- 270 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Vaccine Response
Systems Biological Assessment of Statin Effect on Vaccine Responses
This study is being done to answer the question: Does the use of statin lipid-lowering medication change the effect of influenza vaccine? The research team will use the knowledge gained from answering this question to understand…
- Trial name
- NCT06024096
- Testing
- Atorvastatin, Quadrivalent seasonal influenza vaccine
- Where
- United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Emory University
Influenza
Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Quadrivalent, Influenza Vaccine
The study will evaluate the safety and immunogenicity of the 2014-2015 formulation of Fluzone Quadrivalent vaccine, administered in a 1- or 2-dose schedule, in accordance with the Advisory Committee on Immunization Practices…
- Trial name
- NCT02222870
- Testing
- Fluzone® Quadrivalent Influenza Vaccine, No Preservative
- Where
- 2 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Asthma
Study to Evaluate the Potential Effect of Benralizumab on the Humoral Immune Response to the Seasonal Influenza Vaccination in Adolescent and Young Adult Patients With Severe Asthma
This is a randomized, double-blind, parallel group, placebo-controlled study designed to investigate the potential effect of a fixed dose of benralizumab administered subcutaneously (SC) on antibody responses following seasonal…
- Trial name
- ALIZE (NCT02814643)
- Testing
- Benralizumab, Seasonal influenza virus vaccine
- Where
- 24 sites in United States
- Volunteers
- 103 people
- Sponsor
- AstraZeneca
Healthy Participants
Influenza Virus Vaccine Plus Vitamin A and D Supplements for Prevention of Respiratory Virus Infections in Children
Children are particularly vulnerable to respiratory virus infections, especially influenza. Vitamin A \& D deficiencies are associated with vulnerability to infectious diseases of the respiratory tract.
- Trial name
- NCT02649192
- Testing
- Influenza virus vaccine, Vitamins A and D
- Where
- United States
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- St. Jude Children's Research Hospital
Influenza Prophylaxis
Clinical Trial Assessing the Immunologic Response to a Influenza Vaccine Delivered Using an Jet Injection Device or a Needle Syringe
The primary objective of this study was to evaluate if administration of a seasonal flu vaccine using a jet injector device is comparable to traditional needle and syringe delivery for eliciting an immune response.
- Trial name
- NCT01644149
- Testing
- Stratis Jet Injector, Needle and Syringe, 2011-2012 Fluzone trivalent inactivated influenza vaccine
- Where
- United States
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- PharmaJet, Inc.
Influenza
Immunogenicity of GSK Biologicals' Pandemic Influenza Vaccine (GSK1562902A) at Different Boosting Vaccination Schedules
Today, the leading contender for the next influenza pandemic is H5N1, a strain of avian virus found primarily in domestic and wild birds. Experts warn that the next influenza pandemic is imminent and could be severe.
- Trial name
- NCT00652743
- Testing
- Pandemic influenza vaccine GSK1562902A
- Where
- 6 sites in Hong Kong, Singapore and 2 more
- Volunteers
- 845 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Influenza Virus Vaccine (2012-2013 Formulation)
The aim of this clinical study is to demonstrate safety and immunogenicity of Fluzone vaccine. Objective: To describe the safety of the 2012-2013 formulation of Fluzone vaccine, administered in a 1- or 2-dose schedule, in…
- Trial name
- NCT01691326
- Testing
- Fluzone®: Influenza Virus Vaccine, No Preservative: Pediatric Dose, Fluzone®; Influenza Virus Vaccine, No Preservative
- Where
- 2 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Acute Respiratory Distress Syndrome, Influenza
STIP: Statin Trial for Influenza Patients
To assess the efficacy and safety of oral rosuvastatin in patients with suspected or confirmed influenza who require intensive care unit (ICU) admission due to respiratory distress.
- Conditions
- Acute Respiratory Distress Syndrome, Influenza, H1N1 Influenza
- Trial name
- STIP (NCT00970606)
- Testing
- Rosuvastatin (crestor)
- Where
- 21 sites in United States
- Volunteers
- 7 people
- Sponsor
- Gordon Bernard
Influenza, Fever
Safety of Two Trivalent Influenza Vaccines Evaluated in Children and Adolescents 4 to 17 Years of Age
Evaluate safety and tolerability of TIVa or TIVb vaccine in healthy children and adolescents 4 to 17 years of age.
- Trial name
- NCT01857206
- Testing
- Mammalian cell based flu vaccine, Egg based flu vaccine
- Where
- 34 sites in United States, Australia and 3 more
- Volunteers
- 2,055 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza
Study of a Quadrivalent Influenza Vaccine Administered Via the Intramuscular Route in Children and Adolescents in Taiwan
The aim of the study is to describe the immunogenicity and safety of the new formulation of Quadrivalent Influenza Vaccine (QIV) for the 2013-2014 season in the Northern Hemisphere (NH) in subjects aged 9 to 17 years in Taiwan…
- Trial name
- NCT01967784
- Testing
- Quadrivalent Influenza Vaccine (split virion, inactivated)
- Where
- 2 sites in Taiwan
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
Comparison of Three Licensed Influenza Vaccines
This study will evaluate in detail the way that the immune system responds to three different kinds of flu shots that are licensed in the United States.
- Trial name
- NCT03068949
- Testing
- FluBlok, Fluzone, FluCelVax
- Where
- United States
- Volunteers
- 413 people, healthy volunteers welcome
- Sponsor
- University of Rochester
Influenza
Evaluation of Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2186877A in Adults 65 Years and Older
The purpose of this study is to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals' influenza vaccine GSK2186877A in adults 65 year of age and older.
- Trial name
- NCT00760617
- Testing
- GSK Bio's influenza vaccine GSK2186877A, Fluarix
- Where
- 25 sites in Germany, Netherlands and 1 more
- Volunteers
- 526 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Adaptive Immune Responses and Repertoire in Influenza Vaccination and Infection (SLVP031)
The purpose of this study is provide a better understanding of the adaptive immune response to the licensed flu vaccines. The investigators hope the information learned from this study will help identify and describe important…
- Trial name
- NCT03028987
- Testing
- Fluzone®, FluMist®
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Stanford University
Influenza
Study to Evaluate the Immunogenicity and Safety of 'IL-YANG Quadrivalent Influenza Vaccine Inj.'
This study evaluates the immunogenicity and safety of 'IL-YANG Quadrivalent Influenza Vaccine Inj.' in healthy male and female adults at the age of 19 or older.
- Trial name
- NCT02677493
- Testing
- IL-YANG Quadrivalent Influenza Vaccine, IL-YANG Flu Vaccine Prefilled Syringe, IL-YANG Trivalent Influenza Vaccine
- Volunteers
- 1,794 people, healthy volunteers welcome
- Sponsor
- Il-Yang Pharm. Co., Ltd.
Tetanus, Diphtheria
Confirmatory Study of BK1310 in Healthy Infants
The purpose of this study is to evaluate immunogenicity of BK1310 for all antigens (anti-PRP, diphtheria toxin, pertussis, tetanus toxin, and polio virus), after 3 times of injection, when compared noninferiority with…
- Conditions
- Tetanus, Diphtheria, Pertussis, Poliomyelitis
- Trial name
- NCT03891758
- Testing
- DPT-IPV-Hib, Hib vaccine, DPT-IPV
- Where
- Japan
- Volunteers
- 267 people, healthy volunteers welcome
- Sponsor
- Tanabe Pharma Corporation
Influenza
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Patients ≥65 Years
This phase I/II, randomized, modified double-blind, multi-center study assessed the safety and immunogenicity of a high-dose Quadrivalent influenza vaccine (QIV-HD) in older adults (greater than or equal to [>=] 65 years).
- Trial name
- NCT03233217
- Testing
- QIV-HD by IM, QIV-SD by SC, QIV-HD by SC
- Where
- 2 sites in Japan
- Volunteers
- 175 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
Immunogenicity and Safety Study of FluarixTM Vaccine in Children Who Have Previously Been Vaccinated With PandemrixTM
This study is designed to assess the immunogenicity, reactogenicity and safety following vaccination with GSK Biologicals' FluarixTM vaccine in children who have previously been vaccinated with one dose of PandemrixTM at the age…
- Trial name
- NCT01190215
- Testing
- FluarixTM, HavrixTM Junior (in subjects of 15 years old or below) or HavrixTM (in subjects above 15 years old)
- Where
- Finland
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Acute Respiratory Infection
University of Wisconsin Meditation & Exercise Cold Study
The primary goal of this project is to determine whether behavioral training in mindfulness meditation or moderate intensity sustained exercise will lead to reductions in acute respiratory infection (ARI) illness, such as common…
- Trial name
- MEPARI-2 (NCT01654289)
- Testing
- Mindfulness Meditation, Exercise
- Where
- United States
- Volunteers
- 413 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Influenza
Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine (GSK2282512A) Compared to Fluzone® Quadrivalent in Children 6 to 35 Months of Age
The purpose of this study is to assess the immunogenicity and safety of GSK Biologicals' quadrivalent influenza vaccine (GSK2282512A) compared to Sanofi Pasteur's Fluzone® Quadrivalent in children 6 to 35 months of age.
- Trial name
- NCT02242643
- Testing
- FluLaval™ Quadrivalent, Fluzone® Quadrivalent
- Where
- 66 sites in United States, Mexico
- Volunteers
- 2,432 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline